FIELD: chemistry; medicine.
SUBSTANCE: invention relates to a heterocyclic compound which has the effect of inducing interleukin-1 receptor-associated kinase-M (IRAK-M) protein degradation. Disclosed is a compound represented by the following formula (I): 
where the binder IRAK-M (M) is represented by the following formula (III):
,
where Y, R01, A01, R11, linker (L) and binder E3 ligase (E) are defined in the claims.
EFFECT: invention is expected to be useful for preventing/treating cancer, fibrosis, infectious and other diseases.
8 cl, 1 dwg, 3 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYCYCLIC COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF POLYPEPTIDES OF FAST ACCELERATED FIBROSARCOMA | 2019 |
|
RU2830173C2 |
| COMPOUNDS TARGETING TAU PROTEIN AND RELATED USE THEREOF | 2017 |
|
RU2805523C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
| APOPTOSIS-INDUCING PREPARATIONS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2009 |
|
RU2527450C2 |
| NITROGEN-CONTAINING AROMATIC DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD FOR TREATMENT AND USING | 2003 |
|
RU2310651C2 |
| APOPTOSIS-INDUCING AGENTS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535203C2 |
| BENZIMIDAZOLE AND INDOLE DERIVATIVES AS SELECTIVE 5-HT6 AND/OR 5-HT2A RECEPTOR ANTAGONISTS | 2006 |
|
RU2415138C2 |
| PYRIMIDINE DERIVATIVES | 2008 |
|
RU2455994C2 |
| BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR TREATING CANER AND IMMUNE DISEASES | 2010 |
|
RU2542994C2 |
| ANTIBACTERIAL AGENT | 2000 |
|
RU2269525C2 |
